Literature DB >> 35685055

Treatment of Depression with Vortioxetine in a Patient with Comorbid Major Depressive Disorder and Restless Legs Syndrome: A Case Report.

Barış Yilbaş1.   

Abstract

Many case reports have shown that the use of antidepressants can lead to restless legs syndrome (RLS). Vortioxetine is a new generation antidepressant with a multimodal mechanism of action on serotonin receptors. In this case report, partial improvement in RLS symptoms after treatment with vortioxetine in a patient with a co-diagnosis of major depressive disorder and restless legs syndrome will be discussed. A 59-year-old female patient was admitted to the psychiatry outpatient clinic due to depressive complaints for three months. In the control examination, it was learned that the patient had complaints of RLS that had been going on for about 20 years. RLS symptoms were increased with selective serotonin reuptake inhibitors (SSRI) used by the patient. In the follow-up examination in the first month after vortioxetine treatment, clinically significant improvement was observed in the patient's depressive complaints, while a partial reduction in RLS symptoms was observed. Copyright:
© 2022 Turkish Neuropsychiatric Society.

Entities:  

Keywords:  Antidepressant; dopamine; restless legs syndrome; vortioxetine

Year:  2022        PMID: 35685055      PMCID: PMC9142024          DOI: 10.29399/npa.27827

Source DB:  PubMed          Journal:  Noro Psikiyatr Ars        ISSN: 1300-0667            Impact factor:   1.066


  10 in total

1.  Serotonin uptake into dopamine neurons via dopamine transporters: a compensatory alternative.

Authors:  Feng C Zhou; Klaus-Peter Lesch; Dennis L Murphy
Journal:  Brain Res       Date:  2002-06-28       Impact factor: 3.252

2.  Association of Restless Legs Syndrome With Incident Parkinson's Disease.

Authors:  Szabolcs Szatmari; Daniel Bereczki; Katalin Fornadi; Kamyar Kalantar-Zadeh; Csaba P Kovesdy; Miklos Z Molnar
Journal:  Sleep       Date:  2017-02-01       Impact factor: 5.849

3.  Restless legs syndrome induced by citalopram: a psychiatric emergency?

Authors:  Nader Perroud; Perroud Nader; Coralie Lazignac; Lazignac Coralie; Bertrand Baleydier; Andrei Cicotti; Cicotti Andrei; Susanne Maris; Maris Susanne; Cristian Damsa
Journal:  Gen Hosp Psychiatry       Date:  2007 Jan-Feb       Impact factor: 3.238

Review 4.  Restless legs syndrome.

Authors:  William G Ondo
Journal:  Curr Neurol Neurosci Rep       Date:  2005-07       Impact factor: 5.081

Review 5.  Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health.

Authors:  Richard P Allen; Daniel Picchietti; Wayne A Hening; Claudia Trenkwalder; Arthur S Walters; Jacques Montplaisi
Journal:  Sleep Med       Date:  2003-03       Impact factor: 3.492

6.  Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome.

Authors:  Arthur S Walters; Cheryl LeBrocq; Anjana Dhar; Wayne Hening; Ray Rosen; Richard P Allen; Claudia Trenkwalder
Journal:  Sleep Med       Date:  2003-03       Impact factor: 3.492

7.  Selective serotonin reuptake inhibitors and the risk of restless legs syndrome: a symmetry analysis.

Authors:  Ann-Cathrine Dalgård Dunvald; Daniel Pilsgaard Henriksen; Jesper Hallas; Mette Marie Hougaard Christensen; Lars Christian Lund
Journal:  Eur J Clin Pharmacol       Date:  2020-02-16       Impact factor: 2.953

Review 8.  Drug-Induced Restless Legs Syndrome.

Authors:  Edna Patatanian; Melanie K Claborn
Journal:  Ann Pharmacother       Date:  2018-02-26       Impact factor: 3.154

9.  The safety and tolerability of vortioxetine: Analysis of data from randomized placebo-controlled trials and open-label extension studies.

Authors:  David S Baldwin; Lambros Chrones; Ioana Florea; Rebecca Nielsen; George G Nomikos; William Palo; Elin Reines
Journal:  J Psychopharmacol       Date:  2016-02-09       Impact factor: 4.153

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.